irinotecan has been researched along with 2019 Novel Coronavirus Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C | 1 |
| Jiang, M; Wang, X; Wang, Y; Yao, L; Zhuang, Y | 1 |
| Bodea, R; Mercea, V; Nemes, A; Vidra, R | 1 |
| Lovetrue, B | 1 |
| Dwivedi, T; Gupta, AK; Gupta, R; Meena, JP; Ramachandran, M; Seth, R; Singh, U | 1 |
1 review(s) available for irinotecan and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The recent developments of camptothecin and its derivatives as potential anti-tumor agents.
Topics: Antineoplastic Agents; COVID-19; Drug Liberation; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 2023 |
4 other study(ies) available for irinotecan and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; COVID-19; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Oxaliplatin; Palonosetron; Pandemics; Prospective Studies; Pyridines; Vomiting | 2021 |
Challenges of pancreatic cancer chemotherapy in the COVID-19 era.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Capecitabine; Coronavirus Infections; COVID-19; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Pandemics; Pneumonia, Viral; Romania; SARS-CoV-2 | 2020 |
The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients.
Topics: Comorbidity; COVID-19; COVID-19 Drug Treatment; Critical Illness; Disease Outbreaks; Disease Progression; Drug Discovery; Drug Therapy, Combination; Etoposide; Humans; Irinotecan; SARS-CoV-2; Sepsis; Signal Transduction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Treatment Outcome; Virus Internalization; Virus Replication | 2020 |
Robust and sustained antibody response to SARS-CoV-2 in a child pre and post autologous hematopoietic stem cell transplant.
Topics: Antibodies, Viral; Antineoplastic Agents; Child, Preschool; COVID-19; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunoglobulin G; Immunoglobulin M; Irinotecan; Male; Neuroblastoma; SARS-CoV-2; Temozolomide; Transplantation, Autologous | 2021 |